Development of COX-2-selective NSAIDs significantly reduced the risk of gastrointestinal ulceration, however increased rates of myocardial infarction, heart failure, hypertension and acute renal insufficiency remained. This evidence concerns the gene PTGS2 and hypertensive disorder.